Stockholders' Equity and Noncontrolling Interests - Stock-Based Compensation Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Beginning balance, shares	335	2,586	6,153
Exercised, shares	0	(650)	(333)
Expired, shares	(269)	(1,601)	(3,234)
Ending balance, shares	66	335	2,586
Weighted-average grant date fair value, beginning balance	$ 84.41	$ 106.70	$ 113.36
Weighted-average grant date fair value, exercised	0	99.79	116.48
Weighted-average grant date fair value, expired	77.90	114.17	118.37
Weighted-average grant date fair value, ending balance	$ 110.83	$ 84.41	$ 106.70
Weighted-average contractual remaining life (in years)	10 days
Exercisable shares	66
Weighted-average exercise price	$ 110.83
Weighted-average exercise price exercisable shares	$ 110.83
Compensation expense (credit)	$ 15,000	$ (28,000)	$ (15,000)
Fair value of liability award	$ 1,000	$ 33,000
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Beginning balance, shares	10,000	74,000	76,000
Exercised, shares	0	(64,000)	(2,000)
Ending balance, shares	10,000	10,000	74,000
Weighted-average grant date fair value, beginning balance	$ 80.05	$ 110.19	$ 110.73
Weighted-average grant date fair value, exercised	0	114.90	130.52
Weighted-average grant date fair value, ending balance	$ 80.05	$ 80.05	$ 110.19
Weighted-average contractual remaining life (in years)	3 years 2 months 1 day
Weighted-average exercise price	$ 80.05
Compensation expense (credit)	$ 80,000	$ 328,000	$ 823,000
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Beginning balance, shares	18,316	52,765	100,445
Granted, shares	8,250	8,250	16,500
Exercised, shares	(18,316)	(41,949)	(62,111)
Forfeited, shares	0	(750)	(2,069)
Ending balance, shares	8,250	18,316	52,765
Weighted-average grant date fair value, beginning balance	$ 111.12	$ 106.26	$ 105.97
Weighted-average grant date fair value, granted	113.19	121.93	117.69
Weighted-average grant date fair value, exercised	111.12	106.94	108.90
Weighted-average grant date fair value, forfeited	0	121.93	104.17
Weighted-average grant date fair value, ending balance	$ 113.19	$ 111.12	$ 106.26
Weighted-average contractual remaining life (in years)	10 days
Weighted-average exercise price	$ 111.12
Compensation expense (credit)	$ 1,168,000	$ 1,098,000	$ 3,227,000
Fair value of liability award	$ 971,000	$ 2,426,000